Imatinib mesylate induced immune thrombocytopenia

Rajappa, Senthil; Varadpande, Lalit; Paul, Tanusree; Digumarti, Raghunadharao

doi:10.1080/10428190701615934

Cited by 7 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Возможно, тромбоцитопения также связана с нарушением механизмов репарации ДНК [54]. Снижение числа тромбоцитов может вызывать иматиниб (возникает у 20% пациентов с хроническим миелоидным лейкозом [55]). Причиной этого может быть вызванный иматинибом синтез антител или развитие тромботической микроангиопатии [56].…”

Section: препараты обладающие потенциалом к гипокоагуляцииunclassified

Molecular mechanisms of hemostasis impairment in oncology

Koltsova

Svidelskaya

Shifrin

et al. 2021

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Malignant neoplasms are characterized by the presence of the hemostasis system pathology, predisposing cancer patients to thrombohemorrhagic complications. The pathogenesis of cancer-associated coagulopathy is complex and involves a variety of mechanisms. Tumor cells have the ability to activate the host’s hemostasis system, and this phenomenon is controlled by the same oncogenes that are responsible for neoplastic transformation. In addition to predisposing factors to impaired hemostasis from the side of the disease, the anticancer drugs themselves carry risks of developing coagulation disorders. The pathophysiological basis of this kind of disorders caused by chemotherapy is associated with damage to the endothelium, imbalance of coagulation and anticoagulant proteins, platelet dysfunction and their deficiency. In this article, the authors set themselves the goal of generalizing and updating the current knowledge of the molecular mechanisms that cause thrombohemorrhagic risk in cancer.

show abstract